PortfoliosLab logoPortfoliosLab logo
BBOT vs. ATNM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BBOT vs. ATNM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Oncology Therapeutics, Inc (BBOT) and Actinium Pharmaceuticals, Inc. (ATNM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BBOT achieves a -33.95% return, which is significantly lower than ATNM's -10.29% return.


BBOT

1D
-3.27%
1M
-1.43%
YTD
-33.95%
6M
-27.14%
1Y
3Y*
5Y*
10Y*

ATNM

1D
3.39%
1M
7.96%
YTD
-10.29%
6M
-11.59%
1Y
-24.69%
3Y*
-47.41%
5Y*
-32.18%
10Y*
-31.58%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BBOT vs. ATNM - Yearly Performance Comparison


2026 (YTD)2025
BBOT
BridgeBio Oncology Therapeutics, Inc
-33.95%29.74%
ATNM
Actinium Pharmaceuticals, Inc.
-10.29%-9.93%

Correlation

The correlation between BBOT and ATNM is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (All Time)
Calculated using the full available price history since Aug 13, 2025

0.11

Fundamentals

Market Cap

BBOT:

$661.86M

ATNM:

$38.11M

EPS

BBOT:

-$3.90

ATNM:

-$0.75

Total Revenue (TTM)

BBOT:

$0.00

ATNM:

$90.00K

Gross Profit (TTM)

BBOT:

-$194.00K

ATNM:

$485.00K

EBITDA (TTM)

BBOT:

-$168.31M

ATNM:

-$24.68M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BBOT vs. ATNM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBOT

ATNM
ATNM Risk / Return Rank: 2626
Overall Rank
ATNM Sharpe Ratio Rank: 2424
Sharpe Ratio Rank
ATNM Sortino Ratio Rank: 2626
Sortino Ratio Rank
ATNM Omega Ratio Rank: 2727
Omega Ratio Rank
ATNM Calmar Ratio Rank: 2626
Calmar Ratio Rank
ATNM Martin Ratio Rank: 2727
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBOT vs. ATNM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and Actinium Pharmaceuticals, Inc. (ATNM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

BBOT vs. ATNM - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


BBOTATNMDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.37

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.41

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.39

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.25

-0.26

+0.02

Drawdowns

BBOT vs. ATNM - Drawdown Comparison

The maximum BBOT drawdown since its inception was -44.21%, smaller than the maximum ATNM drawdown of -99.75%. Use the drawdown chart below to compare losses from any high point for BBOT and ATNM.


Loading charts...

Drawdown Indicators


BBOTATNMDifference

Max Drawdown

Largest peak-to-trough decline

-44.21%

-99.75%

+55.54%

Max Drawdown (1Y)

Largest decline over 1 year

-49.46%

Max Drawdown (3Y)

Largest decline over 3 years

-90.09%

Max Drawdown (5Y)

Largest decline over 5 years

-93.20%

Max Drawdown (10Y)

Largest decline over 10 years

-98.37%

Current Drawdown

Current decline from peak

-39.77%

-99.69%

+59.92%

Average Drawdown

Average peak-to-trough decline

-18.98%

-85.39%

+66.41%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.61%

Volatility

BBOT vs. ATNM - Volatility Comparison


Loading charts...

Volatility by Period


BBOTATNMDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.74%

Volatility (6M)

Calculated over the trailing 6-month period

45.97%

Volatility (1Y)

Calculated over the trailing 1-year period

71.26%

67.41%

+3.85%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

71.26%

79.79%

-8.53%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

71.26%

81.37%

-10.11%

Dividends

BBOT vs. ATNM - Dividend Comparison

Neither BBOT nor ATNM has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

BBOT vs. ATNM - Financials Comparison

This section allows you to compare key financial metrics between BridgeBio Oncology Therapeutics, Inc and Actinium Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00K400.00K600.00K800.00K1.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober202600
(BBOT) Total Revenue
(ATNM) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BBOT and ATNM have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for BBOT and ATNM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer